In a significant development for public health, the Indian government is preparing to roll out Rifampicin, a key drug vital for the first-line treatment of tuberculosis (TB), this year. Official sources have confirmed that the production of Rifampicin is at an advanced stage and is expected to be commissioned later in 2025.
Tuberculosis continues to be a significant health challenge in India, with millions affected by the disease each year. To support the ongoing efforts for TB elimination, the consistent supply of essential medications like Rifampicin is crucial. In the fiscal year 2023-24, India imported Rifampicin worth Rs 77 crore, highlighting the importance of domestic production in addressing the needs of TB patients.
In addition to Rifampicin, other essential drugs such as Prednisolone, Betamethasone, and Dexamethasone are also anticipated to be commissioned within the year. These medications play vital roles in treating various conditions, including asthma, allergies, and immune disorders, with Prednisolone and Dexamethasone gaining attention during the COVID-19 pandemic.
Public Health Importance
Approximately 3.5 crore Indians suffer from asthma, and the rising levels of air pollution contribute to a growing incidence of respiratory issues. As the government focuses on enhancing the availability of these critical medications, the initiative aligns with India’s broader public health goals, particularly in increasing self-reliance in healthcare.
Under the Production Linked Incentive (PLI) scheme, Natural Biogenex Private Limited is establishing production facilities in Tumkur, Karnataka, designed to produce 10-15 MT per annum of Prednisolone, Betamethasone, and Dexamethasone. The completion of these projects is expected to ensure an annual domestic supply valued at Rs 150 crore, bolstering India’s ability to meet its medical needs and reduce import dependence.
Self-Reliance in Pharmaceuticals
The Indian pharmaceutical industry ranks as the third largest globally by volume, with exports making up over 50% of its value, which totals approximately USD 50 billion. Despite this, India remains dependent on imports for several bulk drugs, a situation that proved vulnerable during the COVID-19 pandemic. The Indian government’s commitment to achieving Atmanirbharta (self-reliance) is underscored by the ongoing efforts to bolster domestic production capabilities.
Recently, 34 projects under the PLI scheme have been completed with investments exceeding Rs 4,200 crores aimed at manufacturing critical Active Pharmaceutical Ingredients (APIs), including Penicillin-G and KSMs for several antibiotics. These projects reflect a strategic shift towards enhancing fermentation technology in bulk drug manufacturing, particularly in response to previous supply chain challenges.
-Raja Aditya
